BR112016003293A8 - Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos - Google Patents

Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos

Info

Publication number
BR112016003293A8
BR112016003293A8 BR112016003293A BR112016003293A BR112016003293A8 BR 112016003293 A8 BR112016003293 A8 BR 112016003293A8 BR 112016003293 A BR112016003293 A BR 112016003293A BR 112016003293 A BR112016003293 A BR 112016003293A BR 112016003293 A8 BR112016003293 A8 BR 112016003293A8
Authority
BR
Brazil
Prior art keywords
rheumatoid arthritis
neutralizing antibodies
csf neutralizing
treatment
analgesics
Prior art date
Application number
BR112016003293A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016003293A2 (pt
Inventor
Wagner Thomas
Carlsson Malin
Staum Kaltoft Margit
Original Assignee
Takeda Gmbh
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh, Takeda Pharmaceuticals Co filed Critical Takeda Gmbh
Publication of BR112016003293A2 publication Critical patent/BR112016003293A2/pt
Publication of BR112016003293A8 publication Critical patent/BR112016003293A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112016003293A 2013-08-30 2014-09-01 Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos BR112016003293A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361871904P 2013-08-30 2013-08-30
US201361871900P 2013-08-30 2013-08-30
PCT/EP2014/068489 WO2015028657A1 (en) 2013-08-30 2014-09-01 Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics

Publications (2)

Publication Number Publication Date
BR112016003293A2 BR112016003293A2 (pt) 2017-11-21
BR112016003293A8 true BR112016003293A8 (pt) 2022-08-16

Family

ID=51454704

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016003293A BR112016003293A8 (pt) 2013-08-30 2014-09-01 Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos

Country Status (12)

Country Link
US (2) US10745475B2 (enExample)
EP (2) EP3039039B1 (enExample)
JP (4) JP2016536327A (enExample)
KR (3) KR20160044035A (enExample)
CN (2) CN105705518A (enExample)
AU (3) AU2014314053C1 (enExample)
BR (1) BR112016003293A8 (enExample)
CA (1) CA2922251C (enExample)
ES (1) ES2860480T3 (enExample)
MX (2) MX385854B (enExample)
RU (1) RU2714919C2 (enExample)
WO (1) WO2015028657A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103191409A (zh) 2003-05-15 2013-07-10 Dmi生物科学公司 T-细胞介导的疾病的治疗
CA2846598C (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
KR101953706B1 (ko) 2016-09-19 2019-03-05 아이-맵 항-gm-csf 항체 및 이것의 사용
CN107840885B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
WO2018144773A1 (en) 2017-02-01 2018-08-09 Yale University Treatment of diuretic resistance
JP7395479B2 (ja) * 2018-01-05 2023-12-11 ノヴォ ノルディスク アー／エス 免疫抑制なしにｉｌ－６媒介性炎症を処置する方法
WO2019178379A2 (en) * 2018-03-14 2019-09-19 Indiana University Research And Technology Corporation Precision medicine for pain: diagnostic biomarkers, pharmacogenomics, and repurposed drugs

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JPS59147297A (ja) 1983-02-10 1984-08-23 株式会社日立製作所 原子炉圧力容器の耐震構造
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3583880D1 (de) 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
GB8624899D0 (en) 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5070013A (en) 1988-05-31 1991-12-03 Schering Corporation Immunochemical assay for human granulocyte-macrophage colony stimulating factor
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
DK1071752T3 (da) 1998-04-21 2003-10-20 Micromet Ag CD19xCD3-specifikke polypeptider og anvendelsen deraf
ATE555794T1 (de) 2000-02-14 2012-05-15 Mitsubishi Tanabe Pharma Corp Heilmittel gegen hepatitis
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
JP2006500905A (ja) 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
PL215168B1 (pl) 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
EP2108660A1 (en) 2002-10-30 2009-10-14 Genentech, Inc. Inhibition of IL-17 production
US7691379B2 (en) 2004-04-12 2010-04-06 Medimmune, Llc Anti-IL-9 antibody formulations
ATE435238T1 (de) 2004-05-05 2009-07-15 Micromet Ag Herstellung eines einkettigen fv antikörperfragments
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1828250A2 (en) 2004-12-16 2007-09-05 Genentech, Inc. Methods for treating autoimmune disorders
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
MX2007012569A (es) 2005-04-18 2007-12-06 Micromet Ag Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos.
PT1888643E (pt) 2005-05-18 2015-01-14 Morphosys Ag Anticorpos anti-fec-gm e as respectivas utilizações
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
KR101486183B1 (ko) 2006-02-08 2015-01-28 모르포테크, 인크. 항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
SI1999152T1 (sl) 2006-03-27 2013-02-28 Medimmune Limited Vezni äślen za gm-csf receptor
CN101605547A (zh) * 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法
WO2009002521A2 (en) 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PL2215119T3 (pl) 2007-11-13 2013-06-28 Evec Inc Przeciwciała monoklonalne, które wiążą się z hGM-CSF i kompozycje lecznicze je zawierające
WO2009134805A2 (en) * 2008-04-28 2009-11-05 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
MX2010011309A (es) 2008-04-29 2010-12-14 Micromet Ag Inhibidores de gm-csf e il-17 para terapia.
JP5674677B2 (ja) 2008-12-22 2015-02-25 ザ ユニバーシティー オブ メルボルンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｅｌｂｏｕｒｎｅ 疼痛治療
JP2012530047A (ja) 2009-05-05 2012-11-29 モルフォシス・アー・ゲー 多発性硬化症のための治療
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
AU2010338305A1 (en) 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
JP6239517B2 (ja) * 2011-10-10 2017-11-29 メディミューン リミテッド 関節リウマチの治療法
HK1208231A1 (en) * 2012-09-20 2016-02-26 Morphosys Ag Treatment for rheumatoid arthritis
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) * 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
JP6346389B1 (ja) 2016-08-03 2018-06-20 古河電気工業株式会社 金属粒子含有組成物

Also Published As

Publication number Publication date
EP3889178A1 (en) 2021-10-06
JP2016536327A (ja) 2016-11-24
US20160355584A1 (en) 2016-12-08
CN105705518A (zh) 2016-06-22
WO2015028657A1 (en) 2015-03-05
KR20160044035A (ko) 2016-04-22
MX2021010472A (es) 2021-10-01
BR112016003293A2 (pt) 2017-11-21
AU2014314053C1 (en) 2023-11-02
US10745475B2 (en) 2020-08-18
US20210171620A1 (en) 2021-06-10
AU2014314053B2 (en) 2020-03-12
US11795216B2 (en) 2023-10-24
JP2022105160A (ja) 2022-07-12
CA2922251C (en) 2023-10-17
MX2016002177A (es) 2016-06-28
ES2860480T3 (es) 2021-10-05
KR20240090993A (ko) 2024-06-21
AU2020203917A1 (en) 2020-07-02
AU2023210647A1 (en) 2023-10-12
EP3039039A1 (en) 2016-07-06
CA2922251A1 (en) 2015-03-05
RU2016109944A (ru) 2017-10-06
JP2024123249A (ja) 2024-09-10
AU2014314053A1 (en) 2016-02-11
RU2714919C2 (ru) 2020-02-21
JP2020109108A (ja) 2020-07-16
CN118178647A (zh) 2024-06-14
RU2016109944A3 (enExample) 2018-07-09
EP3039039B1 (en) 2021-03-10
MX385854B (es) 2025-03-18
KR20220045064A (ko) 2022-04-12

Similar Documents

Publication Publication Date Title
BR112016003293A8 (pt) Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
BR112014008764A8 (pt) Usos de um anticorpo, anticorpo, composição farmacêutica e combinação para o tratamento de artrite reumatoide
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
BR112015021134A2 (pt) conjugados de fármaco e anticorpo
EA201690633A1 (ru) Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
BR112019005328A2 (pt) composição farmacêutica líquida
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
BR112015029395A2 (pt) Anticorpos anti-b7-h5 e seus usos
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
BR112016019176A2 (pt) anticorpos il-21
BR112015023262B8 (pt) Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112015015870A2 (pt) composição farmacêutica
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
BR112015021979A2 (pt) Anticorpos humanos para grem1
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
EA201690159A1 (ru) Способы и композиции для лечения рака
BR112017005209A2 (pt) compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso
EA201592203A1 (ru) Способы лечения таупатии
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
BR112012005957A2 (pt) compostos tricíclicos e usos farmacêuticos dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.